Clinical Trial Detail

NCT ID NCT02924233
Title Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Symphogen A/S
Indications

lung squamous cell carcinoma

Therapies

Nivolumab + SYM004

Nivolumab

Age Groups: adult senior

No variant requirements are available.